minimised toxicity and easy handling. The current portfolio covers triturations of selenium, chromium, copper, molybdenum and iodine. Custom-made blended triturations can be provided on request.

Dr. Paul Lohmann's portfolio has been newly extended with the introduction of the Low Endotoxin Mineral Salts product line, indicated for the production of parenteral, dialysis and ophthalmic products. This product range is produced on a new, dedicated production line. At present, nine different mineral salts based on calcium, magnesium, potassium and sodium are already available in a low-endotoxin quality and it is likely that this product line will be expanded.

FURTHER INFORMATION
Dr. Paul Lohmann GmbH KG
TEL: +49 5155 630
FAX: +49 5155 63118
EMAIL: sales@lohmann4minerals.com
WEBSITE: www.lohmann4minerals.com

Invisible protection

AlpVision Cryptoglyph covert brand protection is now recognised as a mature solution with major deployments protecting over a billion products worldwide. The top 100 pharmaceutical firms have now adopted Cryptoglyph invisible marking, which is fully compatible with the industrial production of billions of pharmaceutical products and the requirements of the relevant health authorities.

Cryptoglyph is the only security process in the world that provides invisible marking with standard ink and printing processes including offset, rotogravure, flexo, laser and inkjet. This means it can be easily integrated into any existing packaging production line. The Cryptoglyph file is simply embedded into the digital image file of the packaging before printing, without any modification of the packaging design. It can protect aluminium or polymer blister packs, as well as folding boxes. A simple capture of a part of the packaging with a mobile phone camera or an ordinary scanner is enough to get the genuine or fake verdict in a few seconds.

A technological solution alone cannot provide suitable, industry-compatible brand protection. Many new high-tech systems fail because they do not take into account the realities of producing large volumes (sometimes billions) of pharmaceutical goods; hundreds of production centres can be involved, each with its own workflow and a number of packaging suppliers.

To protect the many products and stock keeping units that are manufactured and managed by multinational brands, the technology must be embedded into a safe system that complies with many strict rules established by these large firms and the relevant health authorities.

Cryptoglyph brand-protection solutions fully meet the requirements of FDA 21 CFR Part 11 ERES and the FDA Revitalization Act S.1082 for medicines delivered in the USA. The company has completed major deployments for very large pharmaceutical and fast-moving consumer goods manufacturers operating worldwide.

The real breakthrough provided by AlpVision’s Cryptoglyph solutions opens unique opportunities for pharmaceutical manufacturers to rapidly deploy covert brand protection and grey market identification solutions worldwide, under their sole control and with a single point of contact. They can continue using their current packaging manufacturers without any additional hardware or security ink and they don’t have to modify their packaging designs.

FURTHER INFORMATION
AlpVision SA
TEL: +41 21 948 6464
FAX: +41 21 948 6465
EMAIL: avinfo@alpvision.com
WEBSITE: www.alpvision.com

Hazardous expertise

Valsynthes is a subsidiary of Société Suisse des Explosifs. Since its foundation in 1894, the group has acquired broad experience in the field of explosives, which has developed into expertise in hazardous and high-energy chemistry for the pharmaceutical industry.

Valsynthes is dedicated to custom synthesis and contract manufacturing of intermediates, API and pharmaceutical intermediates. The company provides customers with complete solutions from process development to industrial production, from preclinical to commercial quantities. Services include process validation, stability testing and cGMP preparation.

The prime objective of Valsynthes is to provide a strong partnership with its customers, and it is ready to meet their expectations through confidentiality, responsiveness, superior quality and ethical performance. Valsynthes is certified ISO 9001 and is cGMP approved.

The principles of health, safety and environmental protection, as well as a commitment to the Responsible Care programme are integral parts of the company’s quality system. It has facilities for the treatment of acids and waste water, distillation towers for organic solvents and an incinerator for waste products.

FURTHER INFORMATION
Valsynthes
TEL: +41 27 922 7111
FAX: +41 27 922 7200
EMAIL: info@valsynthes.ch
WEBSITE: www.valsynthes.ch

Route optimisations

Syncom has worked on route optimisations for medicinal chemistry groups for a number of pharmaceutical industries for many years. The work includes synthesis of material for toxicity studies and route scouting and optimisation.

For route optimisations, clients provide Syncom with lab-scale procedures. Focus is generally on variation of reaction media, reaction temperatures and reagents, and the type and amount of catalysts used. Work-up and purification methods are adjusted to avoid large-scale column chromatography and to reduce the number